{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-207601","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.449551+00:00","generated_at":"2026-05-14T22:37:57.012084+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003","bullets":["100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.","Favorable safety: no Grade >3 CRS or ICANS observed; 44 patients dosed across three studies to date.","Median progression-free survival of 23.1 months in rrMM patients, including those with extramedullary disease.","All 10 evaluable REDEEM-1 patients achieved CR per IMWG criteria; one prior BCMA CAR-T patient did not respond.","Company plans to meet with FDA later this year to discuss initiating a U.S. registrational study."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-207601","json":"https://secwatch.observer/filing/0001193125-26-207601.json","markdown":"https://secwatch.observer/filing/0001193125-26-207601.md","text":"https://secwatch.observer/filing/0001193125-26-207601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526207601/0001193125-26-207601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526207601/d93617d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:37:57.012084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}